{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:39:52Z","timestamp":1789544392609,"version":"build-2803163510"},"reference-count":54,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The US Food and Drug Administration approval of brentuximab vedotin (BV) in 2011 marked an important milestone in the management of classical Hodgkin lymphoma (HL). Although initially approved for use in the relapsed or refractory setting, its high efficacy and favorable toxicity profile led to numerous studies evaluating BV in the front-line, second-line, and posttransplant settings. BV is now approved for use (in combination with chemotherapy) as frontline treatment of advanced-stage patients and as maintenance therapy following autologous stem cell transplant. Additional studies demonstrate its promise as second-line therapy and for elderly patients, as well. Although studies have demonstrated its promise in multiple settings, the ideal timing for use of BV is evolving. Studies evaluating individualized treatment strategies will ultimately define the optimal place for BV in HL treatment.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.207","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:59Z","timestamp":1555452839000},"page":"207-212","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy"],"prefix":"10.1182","volume":"2018","author":[{"given":"Alison J.","family":"Moskowitz","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2019111601071830300_B1","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111601071830300_B2","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","article-title":"A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies","volume":"111","author":"Bartlett","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111601071830300_B3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Forero-Torres","year":"2009","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111601071830300_B4","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjh.13152","article-title":"A phase 1 dose-escalation study of XmAb\u00ae 2513 in patients with relapsed or refractory Hodgkin lymphoma","volume":"168","author":"Kumar","year":"2015","journal-title":"Br J Haematol"},{"issue":"19","key":"2019111601071830300_B5","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J Clin Oncol"},{"issue":"14 suppl","key":"2019111601071830300_B6","article-title":"Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses","volume":"76","author":"Cao","year":"2016","journal-title":"Cancer Res"},{"issue":"12","key":"2019111601071830300_B7","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"18","key":"2019111601071830300_B8","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2014-03-561878","article-title":"Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event","volume":"123","author":"Gandhi","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2019111601071830300_B9","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","volume":"120","author":"Carson","year":"2014","journal-title":"Cancer"},{"issue":"22","key":"2019111601071830300_B10","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111601071830300_B11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"26","key":"2019111601071830300_B12","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2019111601071830300_B13","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"2019111601071830300_B14","first-page":"JCO2018790139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111601071830300_B15","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","article-title":"Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111601071830300_B16","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3324\/haematol.2016.141846","article-title":"Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes","volume":"101","author":"Kumar","year":"2016","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2019111601071830300_B17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.V130.Suppl_1.734.734","article-title":"A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage unfavorable risk Hodgkin lymphoma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"15 suppl","key":"2019111601071830300_B18","first-page":"8505","article-title":"Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: a phase II trial","volume":"33","author":"Abramson","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2019111601071830300_B19","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2016.34.15_suppl.7508","article-title":"A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma","volume":"34","author":"Park","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111601071830300_B20","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111601071830300_B21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111601071830300_B22","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"8852","key":"2019111601071830300_B23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"9323","key":"2019111601071830300_B24","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"2019111601071830300_B25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"issue":"10","key":"2019111601071830300_B26","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease","volume":"13","author":"Josting","year":"2002","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111601071830300_B27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"issue":"12","key":"2019111601071830300_B28","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","article-title":"Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin\u2019s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Baetz","year":"2003","journal-title":"Ann Oncol"},{"issue":"6","key":"2019111601071830300_B29","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"issue":"7","key":"2019111601071830300_B30","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111601071830300_B31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/bjh.12824","article-title":"F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"165","author":"Gentzler","year":"2014","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111601071830300_B32","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/bmt.2013.88","article-title":"Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin\u2019s lymphoma: outcome after high-dose chemotherapy and auto-SCT","volume":"48","author":"Akhtar","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111601071830300_B33","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","article-title":"Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin\u2019s lymphoma responding to prior salvage therapy","volume":"97","author":"Devillier","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"2019111601071830300_B34","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","article-title":"Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation","volume":"17","author":"Smeltzer","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111601071830300_B35","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3109\/10428194.2011.573889","article-title":"Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma","volume":"52","author":"Mocikova","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2019111601071830300_B36","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/cncr.22714","article-title":"Pretransplant positive positron emission tomography\/gallium scans predict poor outcome in patients with recurrent\/refractory Hodgkin lymphoma","volume":"109","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"23","key":"2019111601071830300_B37","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"issue":"22","key":"2019111601071830300_B38","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood.V128.22.1834.1834","article-title":"Safety and activity of brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed\/refractory (Rel\/Ref) classical Hodgkin lymphoma (cHL): initial results of a phase I\/II trial","volume":"128","author":"Cassaday","year":"2016","journal-title":"Blood"},{"issue":"s5","key":"2019111601071830300_B39","first-page":"44","article-title":"Transplant BRaVE: combining brentuximab vedotin with DHAP as salvage treatment in relapsed\/refractory Hodgkin\u2019s lymphoma. A phase 1 dose-escalation study","volume":"101","author":"Hagenbeek","year":"2016","journal-title":"Haematologica"},{"issue":"22","key":"2019111601071830300_B40","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V128.22.1109.1109","article-title":"Brentuximab vedotin plus ESHAP (BRESHAP) is a highly effective combination for inducing remission in refractory and relapsed Hodgkin lymphoma patients prior to autologous stem cell transplant: a trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)","volume":"128","author":"Garcia-Sanz","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019111601071830300_B41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2019111601071830300_B42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1-2 trial","volume":"19","author":"O\u2019Connor","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111601071830300_B43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019111601071830300_B44","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111601071830300_B45","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"20","key":"2019111601071830300_B46","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","article-title":"Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"issue":"9980","key":"2019111601071830300_B47","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"21","key":"2019111601071830300_B48","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood.V120.21.3701.3701","article-title":"Overall survival benefit for patients with relapsed Hodgkin lymphoma treated with brentuximab vedotin after autologous stem cell transplant","volume":"120","author":"Karuturi","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111601071830300_B49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2019111601071830300_B50","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.bbmt.2014.06.037","article-title":"Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111601071830300_B51","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3109\/10428194.2014.930852","article-title":"Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"56","author":"Illidge","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2019111601071830300_B52","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"issue":"S2","key":"2019111601071830300_B53","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hon.2437_51","article-title":"Genotyping of classical Hodgkin lymphoma on the liquid biopsy","volume":"35","author":"Bruscaggin","year":"2017","journal-title":"Hematol Oncol"},{"issue":"23","key":"2019111601071830300_B54","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/207\/1252617\/hem01828.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/207\/1252617\/hem01828.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T03:14:42Z","timestamp":1663298082000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/207\/277574\/Optimizing-the-role-of-brentuximab-vedotin-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.207","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}